STOCK TITAN

bioAffinity Tech - BIAF STOCK NEWS

Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.

bioAffinity Technologies Inc (BIAF) delivers pioneering noninvasive diagnostics for early cancer detection through advanced flow cytometry solutions. This dedicated news center provides investors and medical professionals with timely updates on the company’s scientific advancements and strategic growth.

Access official press releases covering regulatory milestones, clinical study results, and partnership agreements. Key focus areas include developments around the CyPath Lung test, licensing expansions, and financial performance reports. Our curated feed ensures you stay informed about BIAF’s contributions to reducing invasive diagnostic procedures in oncology.

Explore updates categorized for clarity: earnings announcements, FDA submissions, collaborative research initiatives, and technological enhancements to cellular analysis platforms. Bookmark this page or check regularly to monitor how bioAffinity’s innovations in cellular oncology are reshaping diagnostic standards.

Rhea-AI Summary

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has closed a $2.6 million registered direct offering and concurrent private placement. The company sold 2,048,294 shares of common stock at $1.30 per share and issued warrants to purchase up to 2,662,782 shares at an exercise price of $1.50 per share. The warrants will be exercisable upon stockholder approval and expire five years from that date. WallachBeth Capital acted as the sole placement agent. The company plans to use the net proceeds for general corporate purposes and working capital. The offering was made pursuant to an effective shelf registration statement, with a prospectus supplement to be filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
private placement offering
-
Rhea-AI Summary

WallachBeth Capital announced that bioAffinity Technologies (Nasdaq: BIAF) has entered into a securities purchase agreement for a $2.66 million registered direct offering and concurrent private placement. The offering includes:

1. 2,048,294 shares of common stock at $1.30 per share in a registered direct offering
2. Common warrants to purchase up to 2,662,782 shares at $1.50 per share in a private placement

The warrants will be exercisable upon stockholder approval and expire five years from approval date. The offering is expected to close around Oct. 21, 2024. WallachBeth Capital is acting as the sole placement agent. The common stock will be issued under an effective shelf registration statement, while the warrants will be issued under a Section 4(a)(2) exemption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.83%
Tags
private placement offering
-
Rhea-AI Summary

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has announced a $2.66 million registered direct offering and concurrent private placement. The company will sell 2,048,294 shares of common stock at $1.30 per share in a registered direct offering. Additionally, in a private placement, it will issue common warrants to purchase up to 2,662,782 shares at an exercise price of $1.50 per share. The warrants will be exercisable upon shareholder approval and expire five years from that date. The offering is expected to close around October 21, 2024, subject to conditions. WallachBeth Capital is acting as the sole placement agent. The common stock will be issued under an effective shelf registration statement, while the warrants will be issued under a Section 4(a)(2) exemption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.83%
Tags
private placement offering
Rhea-AI Summary

bioAffinity Technologies (Nasdaq: BIAF; BIAFW) announced that its VP of Diagnostics, Jennifer Rebeles, Ph.D., contributed to a peer-reviewed paper on flow cytometry guidelines for rare matrix samples. The paper, published in Cytometry Part B: Clinical Cytometry, supports the validation approach used for bioAffinity's CyPath® Lung cancer test.

CyPath® Lung is a noninvasive test for early lung cancer detection, particularly useful for patients with pulmonary nodules. It has shown 92% sensitivity and 87% specificity in detecting lung cancer in nodules 20mm or less. The new guidelines address challenges in validating unique sample types like sputum, which CyPath® Lung uses.

The paper supplements the CLSI Guideline H62 and reflects the increasing use of specialized samples in flow cytometry. It acknowledges the challenges bioAffinity scientists overcame in developing CyPath® Lung, including dealing with high viscosity, inhibitors, and complex cellular mixtures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
none
-
Rhea-AI Summary

bioAffinity Technologies has been awarded a U.S. Federal Supply Schedule contract for its CyPath® Lung test, a noninvasive diagnostic tool for early-stage lung cancer detection. This contract enables the Veterans Health Administration (VHA) and Military Health System to access the test for their patients. The VHA, serving 9.1 million Veterans annually, is the largest integrated healthcare system in the U.S.

Lung cancer is the leading cause of cancer-related death in Veterans, who are 25% more likely to receive a lung cancer diagnosis compared to non-Veterans. The CyPath® Lung test is particularly effective for patients with indeterminate pulmonary nodules detected during low dose computed tomography (LDCT) scans. A recent economic impact study suggests that incorporating CyPath® Lung into the current standard of care could result in significant healthcare cost savings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.71%
Tags
none
-
Rhea-AI Summary

A peer-reviewed economic study published in the Journal of Health Economics and Outcomes Research has found that incorporating bioAffinity Technologies' CyPath® Lung test into the standard care for Medicare patients with positive lung cancer screenings could lead to significant healthcare savings. The study, conducted by researchers from Brooke Army Medical Center and South Texas Veterans Health Care Systems, estimates potential savings of $2,773 per patient, totaling $379 million in 2022.

The savings are attributed to reduced follow-up diagnostic assessments, expensive procedures, and related complications. For private-payer patients, the potential savings are even higher at $6,460 per patient, with a total estimated savings of $895 million if all screened individuals in 2022 were privately insured. The study highlights CyPath® Lung's potential to improve early lung cancer diagnosis while reducing unnecessary procedures and medical complications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
Rhea-AI Summary

bioAffinity Technologies (Nasdaq: BIAF; BIAFW) announced that CFO Michael Dougherty is resigning to accept a position in the Pacific Northwest energy industry. J. Michael Edwards, who served as bioAffinity's consulting CFO from 2014 to 2023 and oversaw the company's IPO in 2022, will return as interim CFO until a permanent replacement is found.

Dougherty will continue in his role until September 15, 2024, assisting with the transition. The company expects a smooth handover due to the strong team and financial processes Dougherty established. Edwards, with over 25 years of experience in corporate finance and accounting, will ensure continuity in the Finance Department.

bioAffinity Technologies, focused on developing noninvasive tests for early-stage cancer detection, will immediately begin searching for a permanent CFO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

bioAffinity Technologies (Nasdaq: BIAF) reported $2.4 million revenue for Q2 2024, driven by growing CyPath® Lung sales. Key highlights include:

- Q2 CyPath® Lung test sales up 217% over Q1 2024
- Expanded sales to 8 states outside Texas
- Raised full-year CyPath® Lung sales forecast by 85%
- Forecasting $9.6 million in 2024 revenues for subsidiary PPLS, up 23% over 2023
- Number of physician offices ordering CyPath® Lung up 144% since Jan. 1, 2024
- Closed a $1.75 million offering to fund growth

The company reported a net loss of $2.1 million for Q2 2024. Cash and equivalents were $0.8 million as of June 30, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
Rhea-AI Summary

bioAffinity Technologies (Nasdaq: BIAF, BIAFW) has announced the closing of a registered direct offering and concurrent private placement, along with a warrant inducement, for total gross proceeds of $1.75 million. The company raised approximately $1,302,083 through the exercise of existing warrants by three accredited investors at a reduced price of $1.25 per share. These investors received new unregistered warrants to purchase additional shares. Additionally, bioAffinity closed a securities purchase agreement with an institutional investor, raising about $450,000 through the sale of common stock and warrants. WallachBeth Capital acted as the sole placement agent and financial advisor for these transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
private placement offering
Rhea-AI Summary

WallachBeth Capital announced that bioAffinity Technologies (NASDAQ: BIAF) has entered into warrant exercise agreements and a securities purchase agreement for aggregate gross proceeds of $1.75 million. The transactions include:

1. Exercise of existing warrants by three accredited investors for 1,041,667 shares at $1.25 per share, generating $1,302,083.

2. Issuance of new warrants to purchase 1,302,083 shares at $1.50 per share.

3. A registered direct offering of 360,000 shares and private placement of warrants to purchase 450,000 shares at a combined price of $1.25, generating $450,000.

The transactions are expected to close on August 5, 2024. WallachBeth Capital is acting as the sole placement agent and financial advisor for these transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.31%
Tags
private placement offering
bioAffinity Tech

Nasdaq:BIAF

BIAF Rankings

BIAF Stock Data

9.07M
13.15M
29.16%
3.44%
0.64%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
SAN ANTONIO